Finder is committed to editorial independence. While we receive compensation when you click links to partners, they do not influence our content.
How to buy Blueprint Medicines Corporation stock | $91.35
Learn how to easily invest in Blueprint Medicines Corporation stock.
Blueprint Medicines Corporation is a biotechnology business based in the US. Blueprint Medicines Corporation shares (BPMC) are listed on the NASDAQ and all prices are listed in US Dollars. Blueprint Medicines Corporation employs 451 staff and has a trailing 12-month revenue of around 0.00.
How to buy shares in Blueprint Medicines Corporation
- Compare share trading platforms.Use our comparison table to help you find a platform that fits you.
- Open your brokerage account. Complete an application with your details.
- Confirm your payment details. Fund your account.
- Research the stock. Find the stock by name or ticker symbol – BPMC – and research it before deciding if it's a good investment for you.
- Purchase now or later. Buy your desired number of shares with a market order or use a limit order to delay your purchase until the stock reaches a desired price.
- Check in on your investment. Optimize your portfolio by tracking your stock.
What's in this guide?
- BPMC shares summary
- Compare share dealing platforms
- Is BPMC stock a buy or sell?
- Stock performance over time
- Can I short BPMC shares?
- Are BPMC shares over-valued?
- Blueprint Medicines Corporation's financials
- How volatile are BPMC shares?
- Does Blueprint Medicines Corporation pay a dividend?
- Other common questions
Blueprint Medicines Corporation stock price (NASDAQ: BPMC)Use our graph to track the performance of BPMC stocks over time.
Blueprint Medicines Corporation shares at a glance
|Latest market close||$91.35|
|52-week range||$66.20 - $125.61|
|50-day moving average||$84.78|
|200-day moving average||$93.68|
|Wall St. target price||$119.69|
|Dividend yield||N/A (0%)|
|Earnings per share (TTM)||$5.66|
Buy Blueprint Medicines Corporation shares from these brokeragesCompare special offers, low fees and a wide range of types of investments among top trading platforms.
*Signup bonus information updated weekly.
The value of any investment can go up or down depending on news, trends and market conditions. We are not investment advisers, so do your own due diligence to understand the risks before you invest.
Is it a good time to buy Blueprint Medicines Corporation stock?
The technical analysis gauge below displays real-time ratings for the timeframes you select. This is not a recommendation, however. It represents a technical analysis based on the most popular technical indicators: Moving Averages, Oscillators and Pivots. Finder might not concur and takes no responsibility.
This chart is not advice or a guarantee of success. Rather, it gauges the real-time recommendations of three popular technical indicators: moving averages, oscillators and pivots. Finder is not responsible for how your stock performs.
Blueprint Medicines Corporation price performance over time
|1 week (2021-07-25)||N/A|
|1 month (2021-07-02)||6.18%|
|3 months (2021-05-05)||0.44%|
|6 months (2021-02-01)||N/A|
|1 year (2020-08-01)||N/A|
|2 years (2019-08-01)||N/A|
|3 years (2018-08-01)||N/A|
|5 years (2016-08-01)||N/A|
Is Blueprint Medicines Corporation under- or over-valued?
Valuing Blueprint Medicines Corporation stock is incredibly difficult, and any metric has to be viewed as part of a bigger picture of Blueprint Medicines Corporation's overall performance. However, analysts commonly use some key metrics to help gauge the value of a stock.
Blueprint Medicines Corporation's P/E ratio
Blueprint Medicines Corporation's current share price divided by its per-share earnings (EPS) over a 12-month period gives a "trailing price/earnings ratio" of roughly 15x. In other words, Blueprint Medicines Corporation shares trade at around 15x recent earnings.
That's relatively low compared to, say, the trailing 12-month P/E ratio for the NASDAQ 100 at the end of 2019 (27.29). The low P/E ratio could mean that investors are pessimistic about the outlook for the shares or simply that they're under-valued.
Blueprint Medicines Corporation's EBITDA
Blueprint Medicines Corporation's EBITDA (earnings before interest, taxes, depreciation and amortisation) is $328.7 million.
The EBITDA is a measure of a Blueprint Medicines Corporation's overall financial performance and is widely used to measure a its profitability.
Blueprint Medicines Corporation financials
|Revenue TTM||$809.1 million|
|Operating margin TTM||39.81%|
|Gross profit TTM||$466.5 million|
|Return on assets TTM||15.86%|
|Return on equity TTM||31.22%|
|Market capitalisation||$5 billion|
TTM: trailing 12 months
Shorting Blueprint Medicines Corporation shares
There are currently 3.3 million Blueprint Medicines Corporation shares held short by investors – that's known as Blueprint Medicines Corporation's "short interest". This figure is 7.1% down from 3.5 million last month.
There are a few different ways that this level of interest in shorting Blueprint Medicines Corporation shares can be evaluated.
Blueprint Medicines Corporation's "short interest ratio" (SIR)
Blueprint Medicines Corporation's "short interest ratio" (SIR) is the quantity of Blueprint Medicines Corporation shares currently shorted divided by the average quantity of Blueprint Medicines Corporation shares traded daily (recently around 727725.66371681). Blueprint Medicines Corporation's SIR currently stands at 4.52. In other words for every 100,000 Blueprint Medicines Corporation shares traded daily on the market, roughly 4520 shares are currently held short.
However Blueprint Medicines Corporation's short interest can also be evaluated against the total number of Blueprint Medicines Corporation shares, or, against the total number of tradable Blueprint Medicines Corporation shares (the shares that aren't held by "insiders" or major long-term shareholders – also known as the "float"). In this case Blueprint Medicines Corporation's short interest could be expressed as 0.06% of the outstanding shares (for every 100,000 Blueprint Medicines Corporation shares in existence, roughly 60 shares are currently held short) or 0.0568% of the tradable shares (for every 100,000 tradable Blueprint Medicines Corporation shares, roughly 57 shares are currently held short).
Such a low SIR usually points to an optimistic outlook for the share price, with fewer people currently willing to bet against Blueprint Medicines Corporation.
Find out more about how you can short Blueprint Medicines Corporation stock.
Blueprint Medicines Corporation share dividends
We're not expecting Blueprint Medicines Corporation to pay a dividend over the next 12 months.
Blueprint Medicines Corporation share price volatility
Over the last 12 months, Blueprint Medicines Corporation's shares have ranged in value from as little as $66.2 up to $125.61. A popular way to gauge a stock's volatility is its "beta".
Beta is a measure of a share's volatility in relation to the market. The market (NASDAQ average) beta is 1, while Blueprint Medicines Corporation's is 0.6844. This would suggest that Blueprint Medicines Corporation's shares are less volatile than average (for this exchange).
Blueprint Medicines Corporation overview
Blueprint Medicines Corporation, a precision therapy company, develops medicines for people with cancer and hematologic disorders, and multiple programs for genomically defined cancers, systemic mastocytosis, and cancer immunotherapy in the United States and Europe. The company is developing avapritinib for the treatment of systemic mastocytosis (SM) and gastrointestinal stromal tumors; BLU-263, an orally available, potent, and KIT inhibitor for the treatment of non-advanced SM and other mast cell disorders; and fisogatinib, an orally available and potent inhibitor, which is in Phase 1b/2 trials for the treatment of advanced hepatocellular carcinoma. It is also developing pralsetinib for the treatment of RET-altered non-small cell lung cancer, altered solid tumors, medullary thyroid carcinoma, and other solid tumors; BLU-701 and BLU-945, a selective and potent investigational inhibitors of double-mutant EGFR harboring, which are in preclinical stage for patient with EGFR-driven NSCLC. In addition, the company is developing BLU-782, an oral and investigational activin-like kinase 2 inhibitor, which is in Phase I clinical trials for the treatment of fibrodysplasia ossificans progressive. It has collaboration and license agreements with Clementia Pharmaceuticals, Inc. ; CStone Pharmaceuticals; Genentech, Inc. ; and F.
Stocks similar to Blueprint Medicines Corporation
Blueprint Medicines Corporation in the news
Blueprint Medicines (BPMC) Misses on Q2 Earnings & Revenues
Blueprint Medicines Corporation (BPMC) CEO Jeff Albers on Q2 2021 Results - Earnings Call Transcript
Blueprint Medicines (BPMC) Reports Q2 Loss, Lags Revenue Estimates
Frequently asked questionsWhat percentage of Blueprint Medicines Corporation is owned by insiders or institutions?
Currently 0.899% of Blueprint Medicines Corporation shares are held by insiders and 103.924% by institutions. How many people work for Blueprint Medicines Corporation?
Latest data suggests 451 work at Blueprint Medicines Corporation. When does the fiscal year end for Blueprint Medicines Corporation?
Blueprint Medicines Corporation's fiscal year ends in December. Where is Blueprint Medicines Corporation based?
Blueprint Medicines Corporation's address is: 45 Sidney Street, Cambridge, MA, United States, 02139-4133 What is Blueprint Medicines Corporation's ISIN number?
Blueprint Medicines Corporation's international securities identification number is: US09627Y1091 What is Blueprint Medicines Corporation's CUSIP number?
Blueprint Medicines Corporation's Committee on Uniform Securities Identification Procedures number is: 09627Y109
More guides on Finder
How to buy Chobani stock when it goes public
Everything we know about the Chobani IPO, plus information on how to buy in.
How to buy Stronghold Digital Mining (SDIG) stock when it goes public
Everything we know about the Stronghold Digital Mining IPO, plus information on how to buy in.
How to buy ROX Financial LP (ROXA) stock when it goes public
Everything we know about the ROX Financial LP IPO, plus information on how to buy in.
How to buy Argus Capital Corp (ARGU) stock when it goes public
Everything we know about the Argus Capital Corp IPO, plus information on how to buy in.
How to buy RenovoRx (RNXT) stock when it goes public
Everything we know about the RenovoRx IPO, plus information on how to buy in.
How to buy Draganfly (DPRO) stock when it goes public
Everything we know about the Draganfly IPO, plus information on how to buy in.
How to buy Society Pass Incorporated (SOPA) stock when it goes public
Everything we know about the Society Pass Incorporated IPO, plus information on how to buy in.
How to buy Guardforce AI Co (GFAI) stock when it goes public
Everything we know about the Guardforce AI Co IPO, plus information on how to buy in.
How to buy IsoPlexis Corporation (ISO) stock when it goes public
Everything we know about the IsoPlexis Corporation IPO, plus information on how to buy in.
How to buy Marpai (MRAI) stock when it goes public
Everything we know about the Marpai IPO, plus information on how to buy in.
Ask an Expert